Clinical Trial: Cemiplimab for Kidney Transplant Recipients With Advanced Cutaneous Squamous Cell Carcinoma

U.S., July 21 -- ClinicalTrials.gov registry received information related to the study (NCT07715734) titled 'Cemiplimab for Kidney Transplant Recipients With Advanced Cutaneous Squamous Cell Carcinoma' on July 11.

Brief Summary: This is a phase II, multicenter, open label, single arm, non-randomized trial using Simon's optimal two-stage design to evaluate the efficacy of cemiplimab in kidney transplant recipients with advanced cutaneous squamous cell carcinoma. The hypothesis being tested is that cemiplimab alongside standardized immune suppression will generate anti-tumor activity without triggering allograft rejection.

Study Start Date: Sept. 30

Study Type: INTERVENTIONAL

Condition: Kidney Transplant Recipient Cutaneous Squamous Cell...